Hua Medtech Top News | The New Journey of a Young Company

时间:

2019-08-13
Company News

        Zhang Songlin, director of the animations The Mindless and the Unhappy and Prince Nezha's Triumph against Dragon King that leave great memory for generations, died of stroke on May 8, 2012.

    It is a big pity that stroke causes huge waste of human’s intellectual wealth.

    Stroke is a major threat to public health with its high incidence, high mortality rate and high disability rate.

    To fight the stroke, governments in China are actively promoting the building of the stroke system. The launch of the programs such as the stroke map, the primary and advanced stroke centers and the emergency 120 centers demonstrates the significant responsibility involved in this combat.

    With this sense of responsibility, Hua Medtech has been focusing on providing integrated solutions to stroke since its founding. The official establishment of Hua Medtech Medical Devices (Suzhou) Co., Ltd. on August 8, 2019 started a new journey of Hua Medtech.


泓懿热点 | 新里程新开拓,我们正年轻

    The cornerstone laying ceremony was held on August 8 in Suzhou, attended by Mr. Pang Junyong, President of BioBAY; Mr. Yuan Zhe, General Manager of REALTON; and Mr. Zhang Wei, CEO of Hua Medtech Medical Devices (Shanghai) Co., Ltd. Mr. Pang Junyong and Mr. Yuan Zhe made speeches to extend their congratulations to Hua Medtech, and highlighted the “unique business model” of Hua Medtech.


    

泓懿热点 | 新里程新开拓,我们正年轻

Mr. Pang Junyong

President of BioBAY, Suzhou


    The establishment of Hua Medtech Medical Devices (Suzhou) Co., Ltd. is a key strategic sector in the overall planning of Hua Medtech. Situated in Area B, Phase II of BioBAY, Suzhou, the Suzhou facility will be built into an R&D and production base of 4608 m2 for stroke-related devices and consumables, which will develop along the new direction of manufacturing and R&D innovation. Zhao Wenyuan, General Manager of Hua Medtech Suzhou, proposes that the future development of the Suzhou branch will follow the direction of growth of a human being. In its early stage, the company will continue to introduce domestic and overseas leading technologies and products and localize them via technical improvement and innovation. At the same time, the company will continuously enhance the team’s manufacturing and R&D capability, pay close attention to the latest technologies, and explore quality products and technologies that meet the clinical needs in China.


    Looking forward into the stroke market in China in the next 5-10 years, CEO of Hua Medtech believes that stroke will remain a pain point and the related technologies will develop along a direction of high efficiency, intellectualization, low cost and systematization. Speed is first demand of stroke treatment; intellectualization means higher efficiency and lower cost of human power and resources; low cost allows treatment for more patients; and systematic solutions are needed in clinical uses, which focus on the outcomes and rehabilitation.


    As a major player in this market, Hua Medtech bases its overall planning on its vision and objective: becoming a healthcare provider of integrated solutions to strokes. The future planning will focus on three strategic directions: marketing, manufacturing and R&D, and data services. Marketing was the focus of the company in its early stage, which developed the market and continued its operation via introduction and integration of products and technologies. The establishment of the Suzhou facility provides strong support for manufacturing and R&D. As an essential part in our integrated solution, the powerful downstream and upstream data chaining and optimized services will help Hua Mdetech expand its market.


    As we have a long way to go in future, we must have a powerful will and open mindset. In the past 2 years, Hua Medtech took root in China’s market based on our core values of “Integrity, Ambition, Respect and Innovation”. We are bringing continuous new energy to the market by treating and curing stroke patients through continuous innovation and win-win cooperation. At the same time we are committed to becoming a healthcare provider of integrated solutions to stroke that creates the greatest value for the community.